Holen Sie sich die Stockscreener-App
9.43
2.18%
-0.21
Schlusskurs vom Vortag:
$9.64
Offen:
$10
24-Stunden-Volumen:
6.11M
Relative Volume:
1.98
Marktkapitalisierung:
$2.06B
Einnahmen:
$52.04M
Nettoeinkommen (Verlust:
$-290.50M
KGV:
-6.478
EPS:
-1.4557
Netto-Cashflow:
$-240.94M
1W Leistung:
+8.39%
1M Leistung:
+12.53%
6M Leistung:
-27.35%
1J Leistung:
+13.21%
1-Tages-Spanne:
$9.37
$10.39
1-Wochen-Bereich:
$8.6188
$10.39
52-Wochen-Spanne:
$6.2301
$16.44
Ocular Therapeutix Inc Stock (OCUL) Company Profile
Firmenname
Ocular Therapeutix Inc
Sektor
Branche
Telefon
781-357-4000
Adresse
14 CROSBY DRIVE, 3RD FLOOR, BEDFORD, MA
Compare OCUL vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
9.43 | 2.06B | 52.04M | -290.50M | -240.94M | -1.4557 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-15 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-04-08 | Eingeleitet | William Blair | Outperform |
| 2025-03-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-03-11 | Eingeleitet | Needham | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-20 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-05-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2024-02-09 | Eingeleitet | BofA Securities | Buy |
| 2023-04-21 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-08-10 | Fortgesetzt | Berenberg | Buy |
| 2021-08-10 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-12-28 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-11-13 | Bestätigt | Raymond James | Strong Buy |
| 2020-08-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-03 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2019-05-21 | Herabstufung | Cowen | Outperform → Market Perform |
| 2019-05-21 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-21 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2018-12-03 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-11-15 | Eingeleitet | Raymond James | Strong Buy |
| 2018-09-07 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-10-24 | Eingeleitet | Guggenheim | Buy |
| 2017-07-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-07-12 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-06-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2017-02-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-11-15 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-08-11 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-02-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2015-10-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2015-08-13 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Ocular Therapeutix Inc Aktie (OCUL) Neueste Nachrichten
Ocular Therapeutix Inc (OCUL) Institutional Confidence - TradingKey
Ocular Therapeutix Inc (OCUL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Pravin Dugel (OCUL) reports bona fide gifts of 100,184 OCULAR THERAPEUTIX shares - Stock Titan
Ocular to submit Axpaxli NDA for wet AMD in Q4 - MSN
OCUL Reiterates by HC Wainwright & Co. -- Price Target Raised to $25.00 - GuruFocus
Stocks making big moves yesterday: Nubank, Ocular Therapeutix, Mondelez, ResMed, and Sonos - Yahoo Finance UK
OCUL Maintained by Baird -- Price Target Raised to $30.00 - GuruFocus
Ocular Therapeutix Inc to Host Investor Day Transcript - GuruFocus
Ocular Therapeutix Inc (OCUL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Ocular Therapeutix Inc (OCUL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Ocular Therapeutix, Inc. (OCUL) Analyst/Investor DaySlideshow (NASDAQ:OCUL) 2026-06-17 - Seeking Alpha
Ocular Therapeutix Inc (OCUL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Transcript : Ocular Therapeutix, Inc.Analyst/Investor Day - marketscreener.com
Ocular Therapeutix (OCUL) Plans NDA Submission for AXPAXLI and T - GuruFocus
Why Ocular Therapeutix (OCUL) Stock Is Up Today - Yahoo Finance
Ocular Therapeutix (OCUL) Advances NDA for Axpaxli with FDA Agre - GuruFocus
Ocular Therapeutix (OCUL) Plans Investor Day to Discuss NDA Subm - GuruFocus
OCUL Stock Is Climbing Ahead Of Investor Day — What Is On The Agenda? - Yahoo Finance
Ocular Therapeutix Maps Regulatory Strategy For Lead Drug Program - Benzinga
Ocular Therapeutix Says Axpaxli New Drug Application Submission to US FDA Planned for Q4 - marketscreener.com
Ocular Therapeutix stock dips on NDA submission timeline - Investing.com
Ocular Therapeutix plans wet AMD drug filing in Q4 2026 - Investing.com
Ocular Therapeutix stock dips on NDA submission timeline By Investing.com - Investing.com Canada
Ocular Therapeutix™ Investor Day To Highlight US FDA Alignment On Axpaxli™ NDA With Submission Planned For Fourth Quarter 2026 - TradingView
Ocular Therapeutix Announces FDA Alignment on AXPAXLI NDA Submission Plans for Wet AMD and Provides Updates on Clinical Trials - Quiver Quantitative
Ocular Therapeutix maps AXPAXLI filing for wet AMD after FDA alignment - Stock Titan
Ocular Therapeutix™ Investor Day to Highlight U.S. FDA Alignment on AXPAXLI™ NDA with Submission Planned for Fourth Quarter 2026 - Yahoo Finance
Ocular Therapeutix Inc (OCUL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Ocular Therapeutix Inc (OCUL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Ocular Therapeutix Inc (OCUL) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Piper Sandler Keeps Their Buy Rating on Ocular Therapeutix (OCUL) - The Globe and Mail
Ocular Therapeutix vs. Prime Medicine: A 2026 Analysis of Medical Innovation StocksNews and Statistics - IndexBox
Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Ocular Therapeutix appoints Jason Robins as CFO and expands stock plan - Investing.com Nigeria
Ocular Therapeutix appoints Jason Robins as CFO and expands stock plan By Investing.com - Investing.com South Africa
Director at Ocular Therapeutix (OCUL) receives RSUs and stock options - Stock Titan
Ocular Therapeutix (OCUL) director granted RSUs and options in new equity awards - Stock Titan
Ocular Therapeutix (OCUL) CFO awarded RSUs and stock options in new equity grant - Stock Titan
Ocular Therapeutix (OCUL) director receives 14,000 RSUs and 44,000 stock options - Stock Titan
Ocular Therapeutix (NASDAQ: OCUL) director receives RSU and option grants - Stock Titan
Ocular Therapeutix (OCUL) director granted RSUs and 44,000 stock options - Stock Titan
Ocular Therapeutix (OCUL) director receives new RSU and stock option awards - Stock Titan
Ocular Therapeutix (NASDAQ: OCUL) expands stock plan and names new CFO - Stock Titan
Ocular Therapeutix, Inc. Appoints Jason Robins as Chief Financial Officer - marketscreener.com
symbol__ Stock Quote Price and Forecast - CNN
Ocular Therapeutix Inc Annual Shareholders Meeting Transcript - GuruFocus
OCUL Q1 2026 Earnings: EPS Misses Estimates as Pipeline Progress Drives Stock HigherGuidance vs Actual - newsline.com
Ocular Therapeutix (OCUL) Edges Lower, Testing Key Support ZoneStandard Deviation - newsline.com
(OCUL) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Ocular Therapeutix CMO Nadia Waheed sells $122k in shares - Investing.com UK
Ocular Therapeutix CMO Nadia Waheed sells $122k in shares By Investing.com - Investing.com South Africa
Finanzdaten der Ocular Therapeutix Inc-Aktie (OCUL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):